These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27705940)

  • 21. SETting OP449 into the PP2A-activating drug family.
    Neviani P; Perrotti D
    Clin Cancer Res; 2014 Apr; 20(8):2026-8. PubMed ID: 24634375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
    Hung MH; Chen YL; Chu PY; Shih CT; Yu HC; Tai WT; Shiau CW; Chen KF
    Oncogene; 2016 Sep; 35(37):4891-902. PubMed ID: 26876205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
    Switzer CH; Cheng RY; Vitek TM; Christensen DJ; Wink DA; Vitek MP
    Oncogene; 2011 Jun; 30(22):2504-13. PubMed ID: 21297667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies.
    Routila J; Mäkelä JA; Luukkaa H; Leivo I; Irjala H; Westermarck J; Mäkitie A; Ventelä S
    Genes Chromosomes Cancer; 2016 Jan; 55(1):69-81. PubMed ID: 26395031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
    Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
    Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
    González-Alonso P; Cristóbal I; Manso R; Madoz-Gúrpide J; García-Foncillas J; Rojo F
    Tumour Biol; 2015 Aug; 36(8):5753-5. PubMed ID: 26234767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.
    Gutierrez A; Pan L; Groen RW; Baleydier F; Kentsis A; Marineau J; Grebliunaite R; Kozakewich E; Reed C; Pflumio F; Poglio S; Uzan B; Clemons P; VerPlank L; An F; Burbank J; Norton S; Tolliday N; Steen H; Weng AP; Yuan H; Bradner JE; Mitsiades C; Look AT; Aster JC
    J Clin Invest; 2014 Feb; 124(2):644-55. PubMed ID: 24401270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
    Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
    J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
    Cristóbal I; Garcia-Orti L; Cirauqui C; Cortes-Lavaud X; García-Sánchez MA; Calasanz MJ; Odero MD
    Haematologica; 2012 Apr; 97(4):543-50. PubMed ID: 22133779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
    Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
    Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line.
    Tüfekçi Ö; Yandım MK; Ören H; İrken G; Baran Y
    Leuk Res; 2015 Mar; 39(3):342-7. PubMed ID: 25557384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A.
    Irie A; Harada K; Araki N; Nishimura Y
    PLoS One; 2012; 7(12):e51242. PubMed ID: 23251465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma.
    Huang Z; Fang Z; Zhen H; Zhou L; Amin HM; Shi P
    Leuk Lymphoma; 2014 Aug; 55(8):1876-83. PubMed ID: 24206093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
    Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
    J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.